Literature DB >> 30051353

Loss of Brain Norepinephrine Elicits Neuroinflammation-Mediated Oxidative Injury and Selective Caudo-Rostral Neurodegeneration.

Sheng Song1, Lulu Jiang1,2, Esteban A Oyarzabal1,3, Belinda Wilson1, Zibo Li3, Yen-Yu Ian Shih3, Qingshan Wang4,5, Jau-Shyong Hong6.   

Abstract

Environmental toxicant exposure has been strongly implicated in the pathogenesis of Parkinson's disease (PD). Clinical manifestations of non-motor and motor symptoms in PD stem from decades of progressive neurodegeneration selectively afflicting discrete neuronal populations along a caudo-rostral axis. However, recapitulating this spatiotemporal neurodegenerative pattern in rodents has been unsuccessful. The purpose of this study was to generate such animal PD models and delineate mechanism underlying the ascending neurodegeneration. Neuroinflammation, oxidative stress, and neuronal death in mice brains were measured at different times following a single systemic injection of lipopolysaccharide (LPS). We demonstrate that LPS produced an ascending neurodegeneration that temporally afflicted neurons initially in the locus coeruleus (LC), followed by substantia nigra, and lastly the primary motor cortex and hippocampus. To test the hypothesis that LPS-elicited early loss of noradrenergic LC neurons may underlie this ascending pattern, we used a neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) to deplete brain norepinephrine. DSP-4 injection resulted in a time-dependent ascending degenerative pattern similar to that generated by the LPS model. Mechanistic studies revealed that increase in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-2 (NOX2)-dependent superoxide/reactive oxygen species (ROS) production plays a key role in both LPS- and DSP-4-elicited neurotoxicity. We found that toxin-elicited chronic neuroinflammation, oxidative neuronal injuries, and neurodegeneration were greatly suppressed in mice deficient in NOX2 gene or treated with NOX2-specific inhibitor. Our studies document the first rodent PD model recapturing the ascending neurodegenerative pattern of PD patients and provide convincing evidence that the loss of brain norepinephrine is critical in initiating and maintaining chronic neuroinflammation and the discrete neurodegeneration in PD.

Entities:  

Keywords:  Chronic neuroinflammation; Norepinephrine depletion; Oxidative and nitrosylative neuronal injuries; Parkinson’s diseases; Progressive neurodegeneration

Mesh:

Substances:

Year:  2018        PMID: 30051353      PMCID: PMC6348128          DOI: 10.1007/s12035-018-1235-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  71 in total

1.  Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide.

Authors:  B Liu; J W Jiang; B C Wilson; L Du; S N Yang; J Y Wang; G C Wu; X D Cao; J S Hong
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia.

Authors:  W G Kim; R P Mohney; B Wilson; G H Jeohn; B Liu; J S Hong
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 3.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.

Authors:  H Braak; U Rüb; W P Gai; K Del Tredici
Journal:  J Neural Transm (Vienna)       Date:  2003-05       Impact factor: 3.575

4.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 5.  Depression and Parkinson's disease: a review.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  1992-04       Impact factor: 18.112

6.  Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease.

Authors:  Michael T Heneka; Elena Galea; Vitaliy Gavriluyk; Lucia Dumitrescu-Ozimek; JoAnna Daeschner; M Kerry O'Banion; Guy Weinberg; Thomas Klockgether; Douglas L Feinstein
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 7.  Inflammation in neurodegenerative disease--a double-edged sword.

Authors:  Tony Wyss-Coray; Lennart Mucke
Journal:  Neuron       Date:  2002-08-01       Impact factor: 17.173

8.  Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation.

Authors:  Suzana Gispert; Domenico Del Turco; Lisa Garrett; Amy Chen; David J Bernard; John Hamm-Clement; Horst-Werner Korf; Thomas Deller; Heiko Braak; Georg Auburger; Robert L Nussbaum
Journal:  Mol Cell Neurosci       Date:  2003-10       Impact factor: 4.314

9.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.

Authors:  Chris Zarow; Scott A Lyness; James A Mortimer; Helena C Chui
Journal:  Arch Neurol       Date:  2003-03

10.  Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production.

Authors:  Cinzia Dello Russo; Anne I Boullerne; Vitaliy Gavrilyuk; Douglas L Feinstein
Journal:  J Neuroinflammation       Date:  2004-06-30       Impact factor: 8.322

View more
  21 in total

1.  Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions.

Authors:  Sheng Song; Qingshan Wang; Lulu Jiang; Esteban Oyarzabal; Natallia V Riddick; Belinda Wilson; Sheryl S Moy; Yen-Yu Ian Shih; Jau-Shyong Hong
Journal:  Brain Behav Immun       Date:  2019-06-24       Impact factor: 7.217

Review 2.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Activation of the MAC1-ERK1/2-NOX2 Pathway Is Required for LPS-Induced Sustaining Reactive Microgliosis, Chronic Neuroinflammation and Neurodegeneration.

Authors:  Shih-Heng Chen; Shuangyu Han; Chih-Fen Hu; Ran Zhou; Yun Gao; Dezhen Tu; Huiming Gao; Jing Feng; Yubao Wang; Ru-Band Lu; Jau-Shyong Hong
Journal:  Antioxidants (Basel)       Date:  2022-06-20

4.  Protection against glutathione depletion-associated oxidative neuronal death by neurotransmitters norepinephrine and dopamine: Protein disulfide isomerase as a mechanistic target for neuroprotection.

Authors:  Hye Joung Choi; Tong-Xiang Chen; Ming-Jie Hou; Ji Hoon Song; Peng Li; Chun-Feng Liu; Pan Wang; Bao Ting Zhu
Journal:  Acta Pharmacol Sin       Date:  2022-03-28       Impact factor: 7.169

5.  Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Authors:  Laura M Butkovich; Madelyn C Houser; Termpanit Chalermpalanupap; Kirsten A Porter-Stransky; Alexa F Iannitelli; Jake S Boles; Grace M Lloyd; Alexandra S Coomes; Lori N Eidson; Maria Elizabeth De Sousa Rodrigues; Danielle L Oliver; Sean D Kelly; Jianjun Chang; Nora Bengoa-Vergniory; Richard Wade-Martins; Benoit I Giasson; Valerie Joers; David Weinshenker; Malú Gámez Tansey
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

Review 6.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

7.  Pharmacological targeting of β2 -adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease.

Authors:  Eoin O'Neill; Justin D Yssel; Caoimhe McNamara; Andrew Harkin
Journal:  Br J Pharmacol       Date:  2019-12-12       Impact factor: 8.739

Review 8.  Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy.

Authors:  Fillipe M de Araújo; Lorena Cuenca-Bermejo; Emiliano Fernández-Villalba; Silvia L Costa; Victor Diogenes A Silva; Maria Trinidad Herrero
Journal:  Cell Mol Neurobiol       Date:  2021-01-02       Impact factor: 5.046

9.  Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson's disease model.

Authors:  Liyan Hou; Fuqiang Sun; Ruixue Huang; Wei Sun; Dan Zhang; Qingshan Wang
Journal:  Redox Biol       Date:  2019-02-08       Impact factor: 11.799

Review 10.  α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis.

Authors:  Laura M Butkovich; Madelyn C Houser; Malú G Tansey
Journal:  Front Neurosci       Date:  2018-09-11       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.